Improving outcomes in state AIDS drug assistance programs

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 5, 2009, Pages 513-521

  Linas, Benjamin P ^a   Losina, Elena ^a,b,c,d   Rockwell, Annette ^e   Walensky, Rochelle P ^a,b,c   Cranston, Kevin ^e   Freedberg, Kenneth A ^a,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

ADAP; AIDS; Anti HIV agents; CD4 lymphocyte count; Government programs; Resource allocation; Therapeutic use

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; ATOVAQUONE; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PENTAMIDINE; RALTEGRAVIR; TENOFOVIR;

ADULT; AIDS DRUG ASSISTANCE PROGRAM; ARTICLE; CD4 LYMPHOCYTE COUNT; COST CONTROL; DISEASE COURSE; DRUG EFFICACY; FEMALE; GOVERNMENT; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MODEL; MORBIDITY; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS; UNITED STATES; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); PUBLIC ASSISTANCE; RESOURCE ALLOCATION; STATE HEALTH PLANS; TIME FACTORS; UNITED STATES;

EID: 68449095558     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b16d00     Document Type: Article

References (43)

1. Carbaugh A, Kates J, Crutsinger-Perry B, et al. National ADAP Monitoring Project Annual Report. Menlo Park, CA: Henry J. Kaiser Family Foundation; 2008.
2. Health Resources and Service Administration HIV/AIDS Bureau. Maximizing Access to Medications Through Efficient Use of Care Act Resources. Washington, DC; 2005.
3. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38:96-103.
4. Reif S, Whetten K, Thielman N. Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the southeastern United States. South Med J. 2007;100:775-781.
5. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr. 2000;25:115-123.
6. Grant WC, Jhaveri RR, McHutchison JG, et al. Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology. 2005;42:1406-1413.
7. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1-17; quiz CE1-4.
8. Bassett IV, Farel C, Szmuilowicz ED, et al. HIV/AIDS: AIDS Drug Assistance Programs in the era of routine HIV testing, Clin Infect Dis. 2008;47:695-701.
9. National Alliance of State and Territorial AIDS Directors. AIDS Drug Assistance Programs and Cost Containment Strategies: Eligibility Criteria Options. Washington, DC: National Alliance of State and Territorial AIDS Directors; 2007.
10. National Alliance of State and Territorial AIDS Directors. AIDS Drug Assistance Programs and Cost Containment Strategies: Waiting List Management. Washington, DC: National Alliance of State and Territorial AIDS Directors; 2007.
11. National Alliance of State and Territorial AIDS Directors. AIDS Drug Assistance Programs and Cost Containment Strategies: Managing Prescription Utilization. Washington, DC: National Alliance of State and Territorial AIDS Directors; 2007.
12. Linas BP, Zheng H, Losina E, et al. Optimizing resource allocation in United States AIDS drug assistance programs, Clin Infect Dis. 2006;43:1357-1364.
13. Fishman GS. Discrete-Event Simulation: Modeling, Programming, and Analysis. Berlin, Germany: Springer-Verlag; 2001.
14. Robinson S. Simulation: The Practice of Model Development and Use. Hoboken, NJ: John Wiley & Sons; 2004.
15. Shechter SM, Bryce CL, Alagoz O, et al. A clinically based discrete-event simulation of end-stage liver disease and the organ allocation process. Med Decis Making. 2005;25:199-209.
16. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; 2008:1-128. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdoles-centGL.pdf. Accessed September 25, 2008.
17. Lee KJ, Dunn D, Porter K, et al. Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS. 2008;22:1943-1950.
18. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003;163:2187-2195.
19. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441-446.
20. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
21. Multicenter AIDS Cohort Study (MACS). Multicenter AIDS Cohort Study (MACS) Public Dataset: Release PO4. Springfield, VA: National Technical Information Service; 1995.
22. Arias E. United States life tables, 2003. Natl Vital Stat Rep. 2007;54:1-40.
23. Massachusetts Department of Public Health AIDS Bureau. Massachusetts HIV Drug Assistance Program (HDAP) Administrative Dataset FY 1997-2004. Boston, MA: Massachusetts Department of Public Health AIDS Bureau.
24. Samet JH, Freedberg KA, Savetsky JB, et al. Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS. 2001;15:77-85.
25. El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N EnglJ Med. 1998;339:1889-1895.
26. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996;335:392-398.
27. Benson CA, Williams PL, Cohn DL, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis. 2000;181:1289-1297.
28. Ioannidis JP, Cappelleri JC, Skolnik PR, et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156:177-188.
29. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
30. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-540.
31. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685-694.
32. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711-718.
33. Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin. 2005;21:1683-1692.
34. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261-1269.
35. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005;40:404-412.
36. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824-831.
37. Freedberg KA, Scharfstein JA, Seage GR III, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279:130-136.
38. Women's Interagency HIV Study (WIHS) Dossier. October 2008. Available at: http://statepiaps.jhsph.edu/wihs/Invest-info/dossier.pdf. Accessed January 9, 2008.
39. Smith VK. State budget cuts: how will health care fare in FY 2009? Presented at: the National Health Policy Forum; July 11, 2008; Washington, DC. Available at: http://www.nhpf.org/library/handouts/Smith.slides-07-11-08.pdf. Accessed January 9, 2009.
40. Matt V Budget gap estimated as high as $1.5 billion; service cuts, layoffs expected. Boston Globe. October 15, 2008. Section B, page 1. Available at: http://www.boston.com/news/local/articles/2008/10/15/mass-short- by-as-much-as-15b/.
41. Associated Press. State's expected shortfall shoots up, may force deep cuts. Tuscon Citizen. May 30, 2008.
42. Kitahata MM, Gange SJ, Moore RD, The North American AIDS Cohort Collaboration On ReSearch And Design. Initiating rather than deferring HAART at a CD4+ count between 351-500 cells/mm3 is associated with improved survival. Program and abstracts of the 48th ICAAC/46th IDSA; October 25-28, 2008; Washington, DC. Abstract H-896b.
43. Richard Fausset and Nicholas Riccardi. States face new budget shortfalls. Los Angeles Times. October 19, 2008. Section A, page 1.